Bone Biologics Corporation (BBLG)
NASDAQ: BBLG · Real-Time Price · USD
1.220
-0.060 (-4.69%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Bone Biologics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 2.17 | 2.09 | 2.52 | 2.09 | 1.02 | |
| Research & Development | 1.06 | 2.13 | 6.91 | 1.58 | 0.08 | |
| Operating Expenses | 3.23 | 4.22 | 9.43 | 3.67 | 1.1 | |
| Operating Income | -3.23 | -4.22 | -9.43 | -3.67 | -1.1 | |
| Interest Expense | - | - | - | -0.73 | -0.81 | |
| Interest & Investment Income | 0.12 | 0.06 | 0 | - | - | |
| Other Non Operating Income (Expenses) | 0 | 0.05 | 0.89 | 2.91 | - | |
| EBT Excluding Unusual Items | -3.11 | -4.11 | -8.53 | -1.48 | -1.91 | |
| Legal Settlements | - | - | -0.41 | - | - | |
| Other Unusual Items | - | - | - | - | 0.3 | |
| Pretax Income | -3.11 | -4.11 | -8.95 | -1.48 | -1.61 | |
| Net Income | -3.11 | -4.11 | -8.95 | -1.48 | -1.61 | |
| Preferred Dividends & Other Adjustments | - | 3.21 | - | - | - | |
| Net Income to Common | -3.11 | -7.32 | -8.95 | -1.48 | -1.61 | |
| Shares Outstanding (Basic) | 1 | 0 | 0 | - | - | |
| Shares Outstanding (Diluted) | 1 | 0 | 0 | - | - | |
| Shares Change (YoY) | 364.45% | 476.80% | - | - | - | |
| EPS (Basic) | -2.65 | -28.96 | -204.05 | - | - | |
| EPS (Diluted) | -2.65 | -28.96 | -204.05 | - | - | |
| Free Cash Flow | -2.69 | -4.12 | -9.56 | -3.57 | -1.23 | |
| Free Cash Flow Per Share | -2.29 | -16.31 | -217.89 | - | - | |
| EBIT | -3.23 | -4.22 | -9.43 | -3.67 | -1.1 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.